An Open-label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Two Way Cross-over, Single Dose Bioequivalence Study of Pimavanserin 34 mg Capsule of Humanis Sağlık A.Ş., Turkey and NUPLAZID® (Pimavanserin) Capsules of Acadia Pharmaceuticals Inc. San Diego, CA 92130 USA in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

This study aims to compare two different versions of the same medication, Pimavanserin, which is used to treat conditions like hallucinations and delusions. One version is produced by Humanis Sağlık in Turkey, and the other is the established brand NUPLAZID® by Acadia Pharmaceuticals in the USA. The goal is to determine if these two versions of the medication are absorbed into the body in the same way. This type of research is important to ensure that generic versions of medications are just as safe and effective as their brand-name counterparts. Participants in the study are healthy adults who receive a single dose of each version of the medication in different periods, without knowing which one they are taking. This is conducted under fasting conditions, meaning participants do not eat before taking the medication. The study uses a crossover design, where each participant receives both treatments in a random order. Researchers measure how the drug is absorbed in the body to ensure both versions perform equally. Since the study is in the early phase, it primarily focuses on how the body processes the drug rather than its effects on health conditions.